NVS
NOVARTIS AG
NYSE: NVS · Basel, V8 · Healthcare
$155.01-1.13 (-0.72%)Closed
Market Cap$295.78B
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$110.15 – $163.64
Avg Volume1.8M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$155.01+50.7%
Pipeline
Drug candidates sponsored by NOVARTIS · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Unnamed | Prevention of Meningococcal Infection | Completed | 2005-12past | 1 | |
| Phase 4 | Cyclosporine A | Liver Transplant | Completed | 2007-12past | 1 | |
| Phase 4 | Zoledronic acid | Prostate Cancer+1 more | Completed | 2008-03past | 2 | |
| Phase 4 | Rivastigmine transdermal patch | Alzheimer's Disease | Completed | 2009-01past | 1 | |
| Phase 4 | Aspirin, acetaminophen and caffeine | Pain, Migraine | Completed | 2011-03past | 1 | |
| Phase 4 | Vildagliptin | Type 2 Diabetes Mellitus+2 more | Completed | 2011-12past | 3 | |
| Phase 4 | Nilotinib | Chronic Myelogenous Leukemia in Chronic Phase | Completed | 2014-11past | 1 | |
| Phase 4 | Fingolimod | Multiple Sclerosis | Completed | 2015-09past | 1 | |
| Phase 4 | AMN107 | Chronic Myeloid Leukemia (CML) | Withdrawn | 2017-01past | 1 | |
| Phase 4 | QVA149 | Chronic Obstructive Pulmonary Disease | Completed | 2017-09-26past | 1 | |
| Phase 4 | Aliskiren | Hypertension | Withdrawn | 2018-06past | 1 | |
| Phase 4 | Alpelisib | Advanced Breast Cancer | Completed | 2025-06-12past | 1 | |
| Phase 4 | Ruxolitinib | Graft vs. Host Disease+3 more | Recruiting | 2029-05-10 | 2 | |
| Phase 3 | Enteric-Coated Mycophenolate Sodium | Maintenance Renal Transplantation | Completed | 2005-01past | 1 | |
| Phase 3 | FTY720 | Kidney Transplantation | Completed | 2006-03past | 1 | |
| Phase 3 | Certican | Kidney Transplantation | Completed | 2007-03past | 1 | |
| Phase 3 | Everolimus | Heart Transplantation | Completed | 2007-05past | 1 | |
| Phase 3 | Valsartan + amlodipine | Hypertension | Completed | 2007-08past | 1 | |
| Phase 3 | Telbivudine (LdT) | Hepatitis B | Terminated | 2009-02past | 1 | |
| Phase 3 | ASA404 | Non-Small Cell Lung Cancer+2 more | Terminated | 2010-12past | 2 | |
| Phase 3 | Agomelatine (AGO178C) | Major Depressive Disorder | Completed | 2011-07past | 1 | |
| Phase 2 | imatinib mesylate | Malignant Peripheral Nerve Sheath Tumors+1 more | Completed | 2013-04past | 2 | |
| Phase 3 | Letrozole | Breast Cancer | Completed | 2014-09past | 1 | |
| Phase 3 | tacrolimus | Liver Transplantation | Completed | 2015-03past | 1 | |
| Phase 3 | MenACWY-CRM | Meningococcal Disease+1 more | Completed | 2015-07past | 2 | |
| Phase 3 | Bexsero® vaccine (1 dose at study month zero) | Meningoccocal Disease+1 more | Completed | 2015-09past | 1 | |
| Phase 3 | RAD001 | Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant | Completed | 2016-10-03past | 1 | |
| Phase 3 | Secukinumab | Plaque Type Psorisis+1 more | Completed | 2019-07-01past | 2 | |
| Phase 3 | HCQ | Covid-19 | Completed | 2020-07-27past | 1 | |
| Phase 3 | LCZ696 (sacubitril/valsartan) | Acute Myocardial Infarction | Completed | 2021-02-26past | 1 | |
| Phase 3 | LCZ696 | Heart Failure+2 more | Completed | 2021-05-25past | 1 | |
| Phase 3 | Placebo | Post-menopausal Osteoporosis+2 more | Recruiting | 2027-01-29 | 3 | |
| Phase 3 | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Primary Prevention of Atherosclerotic Cardiovascular Disease | Active, not recruiting | 2029-04-16 | 1 | |
| Phase 3 | Ribociclib | Breast Cancer | Recruiting | 2032-12-31 | 2 | |
| Phase 3 | Focalin XR | ADHD | Completed | — | 1 | |
| Phase 1 | AEE788 | Glioblastoma Multiforme | Completed | 2005-11past | 1 | |
| Phase 2 | formoterol | Asthma | Completed | 2007-05past | 1 | |
| Phase 2 | lapatinib | Neoplasms, Breast | Completed | 2007-09-25past | 1 | |
| Phase 2 | LBH589 | Leukemia, Myeloid, Chronic | Terminated | 2008-01-29past | 1 | |
| Phase 1 | ACZ885 | Rheumatoid Arthritis | Completed | 2009-05past | 2 | |
| Phase 2 | Indacaterol maleate 400 μg | Asthma | Completed | 2009-11past | 1 | |
| Phase 2 | Investigational new drug, company code: BGG492 | Seizures+1 more | Completed | 2010-08past | 1 | |
| Phase 2 | rMenB | Meningococcal Disease | Completed | 2010-09past | 1 | |
| Phase 2 | LDE225 0.75% | Sporadic Superficial and Nodular Skin Basal Cell Carcinomas | Terminated | 2011-02past | 1 | |
| Phase 2 | AFQ056 | Huntington's Disease+1 more | Terminated | 2011-08past | 1 | |
| Phase 2 | BYM338 | Sporadic Inclusion Body Myositis | Completed | 2012-05past | 1 | |
| Phase 2 | AIN457 | Crohn's Disease+2 more | Completed | 2014-06past | 2 | |
| Phase 1 | BYL719 | PIK3CA Mutated Advanced Solid Tumors+1 more | Terminated | 2014-12-26past | 1 | |
| Phase 2 | QGE031 | Asthma | Terminated | 2016-03past | 1 | |
| Phase 2 | Deferasirox | Anemia+3 more | Completed | 2016-07-01past | 3 | |
| Phase 2 | Serelaxin | Chronic Heart Failure | Terminated | 2017-01-11past | 1 | |
| Phase 2 | LJN452 | Primary Bile Acid Diarrhea | Completed | 2018-01-25past | 1 | |
| Phase 2 | Deferasirox granule formulation | Transfusion-dependent Anemia | Completed | 2018-05-31past | 1 | |
| Phase 2 | BGJ398 | Solid Tumor+7 more | Completed | 2018-10-08past | 2 | |
| Phase 2 | VAY736 | Pemphigus Vulgaris | Terminated | 2019-09-25past | 1 | |
| Phase 1 | PDR001 | Melanoma+4 more | Completed | 2020-07-21past | 1 | |
| Phase 2 | Capmatinib | Carcinoma, Non-Small-Cell Lung | Completed | 2020-09-07past | 1 | |
| Phase 2 | LFG316 | Non-infectious Intermediate Uveitis+3 more | Completed | 2022-05-24past | 2 | |
| Phase 2 | Eltrombopag | Immune Thrombocytopenia (ITP) | Completed | 2023-09-22past | 1 | |
| Phase 2 | LOU064 | Allergy, Peanut | Completed | 2025-03-11past | 1 | |
| Phase 2 | MAS825 | NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations | Active, not recruiting | 2025-10-14past | 1 | |
| Phase 1 | BION-1301 Single Dose | IgA Nephropathy | Completed | 2026-06-10past | 1 | |
| Phase 2 | Glycopyrronium bromide 25ug | Asthma | Recruiting | 2027-07-30 | 1 | |
| Phase 2 | decitabine | Myelodysplastic Syndromes+1 more | Active, not recruiting | 2028-02-14 | 1 | |
| Phase 2 | Ociperlimab | Triple Negative Breast Cancer | Withdrawn | 2029-07-17 | 1 | |
| Phase 1 | AAA602 | Prostate Cancer | Withdrawn | 2030-03-31 | 1 | |
| Phase 1 | Gimatecan | Advanced Solid Tumors | Completed | 2008-06past | 1 | |
| Phase 1 | Dovitinib | Solid Tumors+1 more | Completed | 2014-10past | 1 | |
| Phase 1 | buparlisib | Recurrent Glioblastoma Multiforme | Completed | 2016-07-07past | 1 | |
| Phase 1 | LDK378 | Normal Hepatic Function+1 more | Completed | 2016-09past | 1 | |
| Phase 1 | INC280 | Solid Tumors | Completed | 2017-07-04past | 1 | |
| Phase 1 | Tisagenlecleucel | Diffuse Large B-cell Lymphoma | Completed | 2021-07-20past | 1 | |
| Phase 1 | Ganaplacide | Malaria | Completed | 2022-05-13past | 1 | |
| Phase 1 | ATF936 | Healthy | Completed | — | 1 | |
| Phase 1 | RKI983 | Glaucoma+1 more | Completed | — | 1 | |
| N/A | Unnamed | Refractive Error | Completed | 2016-12-02past | 1 | |
| N/A | Unnamed | Presbyopia | Completed | 2017-04-01past | 1 | |
| N/A | Sacubitril/Valsartan | Heart Failure, Systolic | Completed | 2019-06-21past | 1 | |
| N/A | Brolucizumab | Age-related Macular Degeneration (AMD) | Completed | 2020-08-01past | 1 | |
| N/A | Unnamed | Breast Cancer | Completed | 2021-04-01past | 1 | |
| N/A | Unnamed | Sickle Cell Disease | Completed | 2023-12-01past | 1 | |
| N/A | Unnamed | Asthma | Recruiting | 2027-03-11 | 1 | |
| N/A | Unnamed | Breast Cancer | Active, not recruiting | 2028-06-30 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for NVS. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.